Eribulin derivative as well as preparation method and medical application thereof

By optimizing the structure of eribulin derivatives, the toxicity problem in clinical applications has been solved, and faster metabolic clearance and higher therapeutic effects have been achieved, especially showing significant advantages in the treatment of diseases such as breast cancer.

CN120774937APending Publication Date: 2025-10-14SHANGHAI QILU PHARMACEUTICAL RESEARCH & DEVELOPMENT CENTRE LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202510394145.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-02
Filing Date
2025-03-31
Publication Date
2025-10-14

AI Technical Summary

Technical Problem

Eribulin has toxicity problems such as peripheral neuropathy and neutropenia in clinical applications, and its metabolic half-life is long, which affects the therapeutic effect and safety.

Method used

A series of eribulin derivatives have been developed by adjusting the ring A, ring B, R1, R2, R3 and other groups in the structure to optimize their metabolic clearance rate, reduce toxicity and improve therapeutic effects.

Benefits of technology

The invention provides eribulin derivatives with faster metabolic clearance rates, reduces toxicity problems, improves therapeutic efficacy and safety, and shows significant advantages in the treatment of diseases such as breast cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120774937A_ABST
    Figure CN120774937A_ABST
Patent Text Reader

Abstract

The invention relates to an eribulin derivative, a preparation method thereof and application of the eribulin derivative in medicine. Specifically, the invention relates to an eribulin derivative as shown in a general formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative and application of the eribulin derivative as a therapeutic agent, especially application of the eribulin derivative in preparation of drugs for treating and / or preventing cancers.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of medicine and relates to an eribulin derivative, a method for preparing the same, and its use in medicine. Specifically, the present disclosure relates to an eribulin derivative represented by general formula (I), a method for preparing the same, a pharmaceutical composition containing the same, and its use as a therapeutic agent, particularly for preparing a medicament for treating and / or preventing cancer. Background Art

[0002] Eribulin is an analog of β-tubulin B with a unique inhibitory effect on microtubule dynamics. It can achieve anti-tumor activity in both anti-mitotic and non-anti-mitotic ways. Eribulin inhibits the polymerization (or growth) of microtubules by binding to the front end of the extending β-tubulin, quickly and effectively blocking the cells in the G2-M phase and destroying the mitotic spindle. Unlike other microtubule inhibitors (such as paclitaxel and vinca alkaloids), eribulin does not affect the microtubule shortening phase. In addition, eribulin can reduce the concentration of free tubulin by triggering the formation of nonproductive tubulin aggregates, thereby further inhibiting the formation of mitotic spindles. Eribulin has demonstrated effects in preclinical tumor models, including vascular remodeling, reversal of epithelial-mesenchymal transition (EMT), and inhibition of tumor cell metastasis and invasion. However, literature reports indicate that eribulin can cause peripheral neuropathy, potentially leading to dose delays, reductions, and discontinuation. Studies have found that among 4,775 patients (including randomized and non-randomized clinical trials) evaluating eribulin as a single agent, the incidence of full-grade peripheral neuropathy and high-grade peripheral neuropathy were 28% (95% CI, 24-32) and 4% (95% CI, 3-5), respectively. The incidence was higher in patients with breast cancer and those undergoing longer treatment. Furthermore, neutropenia is the most common dose-limiting toxicity associated with eribulin therapy. To address this toxicity, there is an urgent need to develop more effective eribulin derivatives into drugs to address clinical needs.

[0003] Preclinical pharmacokinetic studies have shown that eribulin mesylate has a rapid distribution phase and a prolonged elimination phase, with an average elimination half-life of approximately 40 hours. This compares to the shorter half-lives of typical small molecule drugs, typically only a few hours. Therefore, appropriately increasing the clearance of eribulin can significantly reduce its toxicity. Therefore, identifying eribulin derivatives with comparable or superior activity and faster metabolic clearance is a key approach to reducing eribulin's toxicity. Summary of the Invention

[0004] The object of the present disclosure is to provide a compound represented by general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof;

[0005]

[0006] in:

[0007] R 1 and R 2 The atoms it is connected to form

[0008] Ring A is selected from a 4-membered monocyclic heterocyclyl, a 5- to 10-membered spiro heterocyclyl, and a 5- to 10-membered bridged heterocyclyl;

[0009] Ring B is selected from a 5- to 7-membered monocyclic heterocyclyl, a 3-membered monocyclic heterocyclyl, and a 5- to 10-membered heteroaryl;

[0010] or R 1 、R 2 are the same or different and are each independently selected from hydrogen atoms, deuterium atoms, C 1-6 Alkyl, C 1-6 Alkoxy, -C(O)NR n1 R n2 、-C(O)R o1 、-C(O)OR o2 、-S(O) m NR n1 R n2 、-S(O) m R o3 , 3 to 8-membered heterocyclyl, 3 to 8-membered cycloalkyl, 3 to 8-membered cycloalkenyl, 6 to 10-membered aryl and 5 to 10-membered heteroaryl, and R 1 and R 2 At least one of the following is selected from a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group, and a 5- to 10-membered heteroaryl group; wherein the C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 、-C(O)NR n3 R n4 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, hydroxy C 1-6substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl;

[0011] R 3 Selected from hydrogen atoms, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, -C(O)NR n1 R n2 、-C(O)R o1 、-C(O)OR o2 , 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 、-C(O)NR n3 R n4 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl;

[0012] Each R 4 are the same or different and are each independently selected from hydrogen atoms, deuterium atoms, C 1-6 Alkyl, -OR o 、-NR n1 R n2 、-C(O)NR n1 R n2 、-C(O)R o1 、-C(O)OR o2 、-S(O) m NR n1 R n2 、-S(O)m R o3 , 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 、-C(O)NR n3 R n4 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl;

[0013] Each R 5 are the same or different and are each independently selected from deuterium atoms, C 1-6 Alkyl, -OR o 、-NR n1 R n2 、-C(O)NR n1 R n2 、-C(O)R o1 、-S(O) m NR n1 R n2 , 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 、-C(O)NR n3 R n4 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, hydroxy C 1-6substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl;

[0014] R o 、R o1 、R o2 、R o3 、R o4 、R o5 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 , hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl;

[0015] R n1 、R n2 、R n3 and R n4 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C(O)NR n5 R n6 、-C(O)R o1 、-C(O)OR o2 , 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl group, 3 to 8 membered cycloalkenyl group, 6 to 10 membered aryl group and 5 to 10 membered heteroaryl group; wherein, the C 1-6Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n7 R n8 、-C(O)NR n7 R n8 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, C 1-6 Alkoxy, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl;

[0016] or R n1 and R n2 、R n3 and R n4 Together with the nitrogen atoms to which they are attached, they form a 3- to 8-membered heterocyclic group; wherein the 3- to 8-membered heterocyclic group is optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n7 R n8 、-C(O)NR n7 R n8 、-C(O)R o1 、-C(O)OR o2 , hydroxyl, C 1-6 Alkoxy, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl;

[0017] R n5 、R n6 、R n7 and R n8 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, hydroxy C 1-6 alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl;

[0018] m is 0, 1, or 2;

[0019] n is 0, 1, 2, 3 or 4;

[0020] p is 1, 2, 3 or 4; provided that the compound represented by the general formula (I) is not the following CAS number compounds: 1299493-27-8, 1299470-71-5, 1299470-63-5, 253128-81-3, 253128-80-2, 253128-76-6, 1299493-35-8, 1299493-32-5, 1299493-31-4 and 1299493-30-3.

[0021] In some embodiments of the present disclosure, the compound represented by general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: Ring A is selected from a 4-membered monocyclic heterocyclic group, a 7- to 11-membered spiro heterocyclic group and a 7- to 11-membered bridged heterocyclic group.

[0022] In some embodiments of the present disclosure, the compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: Ring B is selected from a 6-membered monocyclic heterocyclic group.

[0023] In some embodiments of the present disclosure, the compound represented by general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: Ring A is selected from

[0024] In some embodiments of the present disclosure, the compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: Ring B is selected from

[0025] In some embodiments of the present disclosure, the compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: each R 4 are the same or different and are each independently selected from a hydrogen atom, a hydroxyl group and HOCH2-.

[0026] In some embodiments of the present disclosure, the compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: R 5 for

[0027] In some embodiments of the present disclosure, the compound represented by general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: Selected from

[0028] In some embodiments of the present disclosure, the compound represented by general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: Selected from

[0029] In some embodiments of the present disclosure, the compound represented by general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: n is 0 or 1.

[0030] In some embodiments of the present disclosure, the compound represented by general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: p is 1.

[0031] In some embodiments of the present disclosure, the compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: R 1 and R 2 At least one of them is selected from an optionally substituted 3- to 8-membered bridged ring group.

[0032] In some embodiments of the present disclosure, the compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: R 1 and R 2 At least one of them is selected from 3- to 8-membered bridged ring groups optionally substituted by an amino group.

[0033] In some embodiments of the present disclosure, the compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: R 1 and R 2 At least one of which is selected from optionally substituted by amino

[0034] In some embodiments of the present disclosure, the compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: R 1 and R 2 At least one selected from

[0035] In another aspect, the present disclosure provides a compound represented by general formula (II), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof;

[0036]

[0037] in:

[0038] R 2 and R 3 are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl, deuterated C 1-6 Alkyl, amino substituted C 1-6 Alkyl, halogenated C 1-6 alkyl, The condition is that R 2 A hydrogen atom or C 1-6 When alkyl, R 3 Not hydrogen or C 1-6 Alkyl, and the compound represented by general formula (II) is not the compound with CAS number 2973388-27-9.

[0039] In some embodiments of the present disclosure, the compound represented by the general formula (II), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: R 3 Selected from hydrogen atoms, methyl groups,

[0040] In some embodiments of the present disclosure, the compound represented by the general formula (II), its stereoisomers or pharmaceutically acceptable salts thereof, wherein: R 2 Selected from hydrogen atoms,

[0041] In some embodiments of the present disclosure, the compound of the present disclosure is not the cas number compound recorded in the following Table 1:

[0042] Table 1

[0043]

[0044]

[0045]

[0046]

[0047] In another embodiment of the present disclosure, the compound, its stereoisomer or pharmaceutically acceptable salt thereof is a compound represented by general formula (IA), its stereoisomer or pharmaceutically acceptable salt thereof;

[0048]

[0049] wherein: Ring C is selected from a 4-membered monocyclic heterocyclyl containing 1 to 3 N atoms, a 5- to 10-membered spiro heterocyclyl, a 5- to 10-membered bridged heterocyclyl, a 5- to 7-membered monocyclic heterocyclyl, and a 3-membered monocyclic heterocyclyl;

[0050] Y is absent or selected from hydrogen atom, hydroxyl group, amino group, -(CH2) r OH, -C(O)(CH2) r OH

[0051] t is 0, 1, 2, 3, or 4;

[0052] r is 0, 1, 2, or 3;

[0053] Each R 6 are the same or different and are each independently selected from deuterium atoms, C 1-6 Alkyl, -OR o 、-NR n1 R n2 、-C(O)NR n1 R n2 、-C(O)R o1 、-S(O) m NR n1 R n2 , 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 、-C(O)NR n3 R n4 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl;

[0054] R o 、R n1 、R n2 、R o1 、R 3 、R n3 、Rn4 、R o4 、R o5 , m is as defined in any embodiment of the present disclosure.

[0055] In another embodiment of the present disclosure, wherein ring C is selected from

[0056] In another embodiment of the present disclosure, wherein Y is selected from -C(O)CH2OH.

[0057] The present disclosure also provides the following compounds, stereoisomers thereof, or pharmaceutically acceptable salts thereof, wherein typical compounds of the present disclosure include but are not limited to any one of the structures in Table 2 below, stereoisomers thereof, or pharmaceutically acceptable salts thereof:

[0058] Table 2

[0059]

[0060]

[0061] In another aspect, the present disclosure provides a compound represented by general formula (IB), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0062]

[0063] in:

[0064] Ab represents an antibody or antigen-binding fragment; L represents a linker connecting Ab and the warhead drug molecule P;

[0065] u is selected from 1 to 8;

[0066] P is The compound shown, its stereoisomer or a pharmaceutically acceptable salt thereof; R 1 、R 2 、R 3 As defined in any aspect of the present disclosure;

[0067] or

[0068] P is The compound shown, its stereoisomer or its pharmaceutically acceptable salt; Ring C, Y, R 6 , t is as defined in any embodiment of the present disclosure.

[0069] In another embodiment of the present disclosure, wherein Selected from the following compound fragments:

[0070]

[0071]

[0072] In another embodiment of the present disclosure, wherein Selected compound fragments:

[0073] In another embodiment of the present disclosure, wherein the L is -L1-L2-L3-L4-, wherein one end of L1 is connected to the Ab, and one end of L4 is connected to the warhead drug molecule; wherein:

[0074] L1 is selected from the following groups, and the end of L1 marked with an asterisk * is connected to the Ab:

[0075]

[0076] L2 is selected from chemical bonds,

[0077]

[0078] The C-terminus of L2 is connected to L3, and the other end is connected to L1;

[0079] a is the same or different at each occurrence and is independently any integer from 0 to 20;

[0080] b is the same or different at each occurrence and is independently any integer from 0 to 20;

[0081] L3 is selected from a polypeptide residue consisting of 2-6 amino acids, and the C-terminus of the polypeptide residue is connected to L4;

[0082] L4 is selected from a chemical bond, -NH-CH2-, The C-terminus is connected to the warhead drug molecule, and the -NH-terminus is connected to L3.

[0083] In another embodiment of the present disclosure, wherein, when L4 is selected from a chemical bond, P is directly connected to L3.

[0084] In another embodiment of the present disclosure, wherein L2 is selected from a chemical bond,

[0085]

[0086]

[0087] In another embodiment of the present disclosure, wherein L3 is selected from GFG, GGFG, GGGFG, GGVA, V-Cit, VA.

[0088] In another embodiment of the present disclosure, wherein L3 is selected from GGFG, VA.

[0089] In another embodiment of the present disclosure, wherein L4 is selected from

[0090] In another embodiment of the present disclosure, wherein L is selected from the following fragments:

[0091]

[0092]

[0093]

[0094] Among them, "*" indicates the position where the linker is connected to the warhead drug molecule, and the other end indicates the position where the linker is connected to the Ab.

[0095] In another embodiment of the present disclosure, wherein Selected from the following excerpts:

[0096]

[0097]

[0098]

[0099]

[0100] In another embodiment of the present disclosure, wherein the Ab is selected from anti-Her2 antibody, anti-Trop2 antibody, and anti-Claudin18.2 antibody.

[0101] In another embodiment of the present disclosure, wherein the Ab is selected from Trastuzumab, Pertuzumab, Sacituzumab, and Zolbetuximab.

[0102] In another embodiment of the present disclosure, the compound, its stereoisomer or pharmaceutically acceptable salt thereof is a compound, its stereoisomer or pharmaceutically acceptable salt thereof represented by the general formula (IB-1):

[0103]

[0104] in:

[0105] Ab, u, ring C, R 6 ,Y,t,R 3 As described in any solution of the present disclosure.

[0106] In another embodiment of the present disclosure, the compound, its stereoisomer or pharmaceutically acceptable salt thereof is a compound represented by general formula (IB-2), its stereoisomer or pharmaceutically acceptable salt thereof:

[0107]

[0108] Ab, u and L are as defined in any of the schemes in this disclosure.

[0109] In another embodiment of the present disclosure, the compound represented by the general formula (IB), the general formula (IB-1), the general formula (IB-2), its stereoisomers or pharmaceutically acceptable salts thereof are selected from:

[0110]

[0111]

[0112]

[0113]

[0114]

[0115] Among them, u is 1-8.

[0116] In another embodiment of the present disclosure, u is 1, 2, 3, 4, 5, 6, 7, or 8.

[0117] In another embodiment of the present disclosure, u is 2-5.

[0118] In another aspect, the present disclosure provides a compound as shown below, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0119]

[0120]

[0121]

[0122]

[0123] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a compound represented by Formula (I), Formula (II), Formula (IA), Formula (IB), Formula (IB-1), Formula (IB-2), Table 2 (and ADC compounds disclosed herein prepared from the compounds shown in Table 2), stereoisomers thereof, or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers.

[0124] The present disclosure further relates to the use of compounds represented by the general formula (I), general formula (II), general formula (IA), general formula (IB), general formula (IB-1), general formula (IB-2), Table 2 (and ADC compounds disclosed in the present disclosure prepared from the compounds shown in Table 2), their stereoisomers or pharmaceutically acceptable salts, or pharmaceutical compositions containing the same in the preparation of medicaments for treating and / or preventing cancer.

[0125] The present disclosure also relates to a method for inhibiting cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound represented by the general formula (I), general formula (II), general formula (IA), general formula (IB), general formula (IB-1), general formula (IB-2), or Table 2 (as well as the ADC compounds disclosed herein prepared from the compounds shown in Table 2), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.

[0126] The present disclosure further relates to a compound represented by the general formula (I), general formula (II), general formula (IA), general formula (IB), general formula (IB-1), general formula (IB-2), Table 2 (and the ADC compound disclosed in the present disclosure prepared from the compound shown in Table 2), a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which is used as a medicine.

[0127] The present disclosure further relates to a compound represented by the general formula (I), general formula (II), general formula (IA), general formula (IB), general formula (IB-1), general formula (IB-2), Table 2 (and the ADC compound disclosed in the present disclosure prepared from the compound shown in Table 2), a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which is used as a drug for treating cancer.

[0128] Preferably, the cancer as described above in the present disclosure is selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer, colon cancer, rectal cancer, colorectal cancer, leukemia, bone cancer, skin cancer, thyroid cancer, pancreatic cancer and lymphoma; preferably selected from breast ductal carcinoma, esophageal squamous cell carcinoma and lung squamous cell carcinoma.

[0129] The active compound may be formulated for administration by any appropriate route, preferably in a unit dosage form, or in a form that a patient can self-administer as a single dose. A unit dosage form of a compound or composition of the present disclosure may be in the form of a tablet, capsule, cachet, bottled solution, powder, granules, lozenge, suppository, reconstituted powder, or liquid formulation.

[0130] The pharmaceutical composition of the present disclosure may contain one or more excipients in addition to the active compound, selected from the following ingredients: fillers (diluents), binders, wetting agents, disintegrants or excipients, etc. Depending on the administration method, the composition may contain 0.1 to 99% by weight of the active compound.

[0131] Pharmaceutical compositions containing the active ingredient may be in a form suitable for oral administration, such as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Oral compositions may be prepared according to any method known in the art for preparing pharmaceutical compositions, and such compositions may contain one or more ingredients selected from the group consisting of sweeteners, flavoring agents, colorants, and preservatives to provide a pleasing and palatable pharmaceutical formulation. Tablets contain the active ingredient and, in admixture, nontoxic, pharmaceutically acceptable excipients suitable for tablet preparation. These excipients may include inert excipients, granulating agents, disintegrants, binders, and lubricants. These tablets may be uncoated or coated using known techniques that mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained-release effect over a longer period of time.

[0132] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to the following: the activity of the specific compound used, the age of the patient, the weight of the patient, the health status of the patient, the behavior of the patient, the diet of the patient, the time of administration, the mode of administration, the rate of excretion, the combination of drugs, the severity of the disease, etc.; in addition, the optimal treatment method such as the mode of treatment, the daily dosage of the compound or the type of pharmaceutically acceptable salt can be verified according to traditional treatment regimens.

[0133] Terminology

[0134] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be considered ambiguous or unclear without a specific definition, but should be understood according to its ordinary meaning.

[0135] The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes in the disclosed compounds include, but are not limited to, isotopes of hydrogen (e.g., deuterium ( 2 H), tritium ( 3 H)); carbon isotopes (e.g. 11 C. 13 C and 14 C); isotopes of chlorine (e.g. 36 Cl); isotopes of fluorine (e.g. 18 F); isotopes of iodine (such as 123 I and 125I); isotopes of nitrogen (e.g. 13 N and 15 N); oxygen isotopes (e.g. 15 O. 17 O and 18 O); isotopes of phosphorus (such as 32 P); and sulfur isotopes (e.g. 35 S). Isotopically labeled compounds of the disclosure can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein using an appropriate isotopically labeled reagent in place of the unlabeled reagent.

[0136] The term "prodrug" refers to certain derivatives of the disclosed compounds that have little or no pharmacological activity themselves, which have cleavable groups and decompose into the disclosed compounds through solvent decomposition or under physiological conditions. The types of prodrugs include, but are not limited to, amides, esters, anhydrides, salts, and the like. The "ester" refers to a derivative formed with a suitable alcohol when the disclosed compound contains an acidic group (such as a carboxylic acid); or a derivative formed with a suitable acid (including an organic acid or an inorganic acid) when the disclosed compound contains a hydroxyl group. Methods for preparing prodrugs are well known to those skilled in the art.

[0137] The term "solvate" refers to an association or complex of one or more solvent molecules with a compound of the present disclosure. The term "hydrate" may be used when the solvent is water. The solvent molecules may be present in stoichiometric or non-stoichiometric amounts.

[0138] The term "nitrogen oxide" or "N-oxide" refers to a derivative formed by further oxidation of the nitrogen atom in a nitrogen-containing group. Common N-oxides include N-oxides of tertiary amines or nitrogen atoms in nitrogen-containing heterocycles. Synthesis methods of N-oxides are well known to those skilled in the art and include oxidation of heterocycles and tertiary amines using peroxyacids such as peracetic acid and m-chloroperbenzoic acid, hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane.

[0139] The compounds of the present disclosure and their salts may exist as isotopic derivatives, and the compounds of the present disclosure include various isotopic derivatives and mixtures thereof.

[0140] The compounds of the present disclosure and their salts may exist in the form of solvates, such as hydrates, and the compounds of the present disclosure include various solvates and mixtures thereof.

[0141] The compounds of the present disclosure and their salts may exist in the form of "N-oxides", and the compounds of the present disclosure include various N-oxides and mixtures thereof.

[0142] The compounds described in the present disclosure, and their pharmaceutically acceptable salts, isotopic derivatives, solvates, and N-oxides have the same or similar biological activities and are all included within the scope of the present disclosure.

[0143] "Optional" or "optionally" means that the event or circumstances described subsequently may but need not occur, and includes both situations in which the event or circumstances occur and do not occur. For example, "alkyl optionally (optionally) substituted with halogen or cyano" includes both situations in which the alkyl is substituted with halogen or cyano and situations in which the alkyl is not substituted with halogen and cyano.

[0144] Unless otherwise specified, the term "alkyl" refers to a group derived from a branched or straight chain saturated aliphatic alkane having the specified number of carbon atoms by removing one hydrogen. For example, "C 1-6 "Alkyl" refers to C1, C2, C3, C4, C5, C6 alkyl, "C 1-6 "Alkyl" is further preferably "C 1-4 Alkyl", "C 1-3 "alkyl"; specific examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, sec-butyl, 2-methylbutyl, 1,1-dimethylbutyl, etc.

[0145] Unless otherwise specified, the term "deuterated alkyl" refers to an alkyl group, wherein alkyl is as defined above, substituted with one or more deuterium atoms.

[0146] Unless otherwise specified, the term "aminoalkyl" refers to an alkyl group substituted with one or more amino groups, wherein alkyl is as defined above.

[0147] Unless otherwise specified, the term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a halogen atom, wherein alkyl is as defined above. 1-6 Examples of haloalkyl groups include, but are not limited to, monofluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, tribromomethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, and the like. Alkyl groups are as defined above.

[0148] Unless otherwise specified, the term "hydroxyalkyl" refers to a group derived from an alkyl group in which one or more hydrogen atoms are replaced by a hydroxy group, wherein the definition of alkyl is as described above. The "hydroxyalkyl" described in the present disclosure includes "hydroxy C 1-6 Alkyl", "Hydroxy C 1-4 alkyl"; specific examples include but are not limited to -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH2CH2CH2OH, wait.

[0149] Unless otherwise specified, the term "hetero" refers to substituted or unsubstituted heteroatoms and oxidized forms of heteroatoms (also known as heteroatoms), wherein the heteroatoms are generally selected from N, O, S, and P, and the oxidized forms generally include NO, SO, S(O)2, and P(O). The nitrogen atom may be substituted, i.e., NR (R is H or other substituents defined herein); the number of atoms in the ring is generally defined as the number of ring members, for example, "3-6 membered heterocycloalkyl" refers to a ring of 3-6 atoms arranged around, each ring optionally containing 1 to 3 heteroatoms and / or heteroatoms, i.e., N, O, S, NO, SO, S(O)2, P(O), or NR, each ring optionally substituted by an R group, where R is a group defined herein.

[0150] Unless otherwise specified, the term "cycloalkyl" refers to a saturated cyclic alkyl group derived from a cycloalkane by removing a hydrogen atom, including monocyclic and polycyclic saturated hydrocarbon groups. Polycyclic saturated hydrocarbon groups refer to polycyclic groups formed by two or more cyclic alkyl structures connected by spiro, bridged, or fused structures. Carbon atoms in the cycloalkyl group may be further oxidized, forming C(O). Unless otherwise specified, "one-membered cycloalkyl" as used herein refers to a monocyclic cycloalkyl group. If the group is polycyclic, it will be specifically designated as a spiro, fused, or bridged ring group. Examples of cycloalkyl groups include "3- to 8-membered cycloalkyl," "3- to 6-membered cycloalkyl," and "3- to 5-membered cycloalkyl." Preferably, the cycloalkyl group is a monocyclic, saturated structure; specific examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

[0151] Unless otherwise specified, "cycloalkenyl" means a cycloalkyl group in which one or more of the ring bonds is a double bond and the cycloalkenyl group is not aromatic. The carbon atoms in the cycloalkenyl group may be further oxidized, i.e., to form C(O). The cycloalkenyl group includes "3- to 8-membered monocyclic cycloalkenyl", "3- to 6-membered cycloalkenyl", "3- to 5-membered cycloalkenyl", and "5- to 6-membered cycloalkenyl". Specific examples include, but are not limited to,

[0152] The term "spirocyclyl" refers to a cyclic structure formed by two or more carbocyclic structures sharing a carbon atom. Optionally, the carbon atoms in the cyclic structure can be oxoed. Specifically include "5 to 15 membered spirocyclyl", "4 to 11 membered spirocyclyl", "6 to 11 membered spirocyclyl", "5 to 10 membered spirocyclyl", "7 to 10 membered spirocyclyl", "6 to 9 membered spirocyclyl", "7 to 8 membered spirocyclyl", "9 to 10 membered spirocyclyl" and the like, and are not limited to the site of attachment to the parent. Specific examples include, but are not limited to: wait.

[0153] The term "bridged cyclic group" refers to a cyclic structure containing 5 to 15 ring carbon atoms formed by two or more carbocyclic structures sharing two non-adjacent carbon atoms. Optionally, the carbon atoms in the cyclic structure can be oxoed. "5 to 15 membered bridged cyclic groups" include, for example, "5 to 11 membered bridged cyclic groups", "6 to 11 membered bridged cyclic groups", "5 to 10 membered bridged cyclic groups", "7 to 10 membered bridged cyclic groups", "6 to 9 membered bridged cyclic groups", "7 to 8 membered bridged cyclic groups", "9 to 10 membered bridged cyclic groups", etc., and are not limited to the connection site with the parent. Specific examples include, but are not limited to: wait.

[0154] Unless otherwise specified, the term "heterocyclyl" refers to a saturated or unsaturated cyclic group (heterocyclyl includes heterocycloalkenyl, the same below) derived from one or more ring carbon atoms in a cycloalkyl group replaced by a heteroatom and / or a heteroatom group. The heteroatom and / or heteroatom group is generally selected from N, O, S, NO, SO, S(O)2, P(O), and NR, wherein the carbon atoms in the heterocyclic ring are optionally oxidized, i.e., forming -C(O); preferably, the heteroatoms are independently selected from 1-3 N and / or O. The heterocyclyl may be a monocyclic heterocyclyl or a polycyclic heterocyclyl, for example, including "3 to 8-membered heterocyclyl", "3 to 8-membered monocyclic heterocyclyl", "3 to 6-membered heterocyclyl", "3 to 5-membered heterocyclyl", "4 to 6-membered heterocyclyl", "5 to 6-membered heterocyclyl", "6-membered heterocyclyl", and 5 to 8-membered monocyclic heterocyclyl. Specific examples include, but are not limited to, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, and the like. When the heterocyclic group contains an unsaturated structure, the heterocyclic group is also called a "heterocycloalkenyl", which means that one or more ring bonds in the "heterocyclic group" are double bonds and the heterocycle is not aromatic. Preferably, the heteroatoms are independently selected from 1-3 N and / or O. The heterocyclic group includes "3 to 8-membered heterocycloalkenyl", "3 to 6-membered heterocycloalkenyl", "3 to 5-membered heterocycloalkenyl", and "5 to 6-membered heterocycloalkenyl". Specific examples include, but are not limited to: wait.

[0155] The term "spiroheterocyclyl" refers to a cyclic structure derived from the replacement of at least one carbon atom in a "spirocyclyl" by a heteroatom / heteroatom group, wherein the heteroatom / heteroatom group is selected from N, O, S, P, NO, SO, S(O)2, P(O) and NR, R is H or any substituent group that may exist, and the "spirocyclyl" is as defined above. It includes but is not limited to a cyclic structure formed by heterocyclic spiroheterocycles and heterocyclic spiroheterocycle alkanes, and is not limited to the connection site with the parent. The spiroheterocycle preferably contains 1-2 heteroatoms selected from NR and / or O, more preferably contains 1 NR and 0-1 NR or O heteroatoms. The spiroheterocycle is preferably a "nitrogen-containing spiroheterocycle", which refers to a spiroheterocycle in which at least one ring atom is NR. The spiroheterocycle includes a 7-11 membered spiroheterocycle, a 7-9 membered spiroheterocycle, a 7-11 membered nitrogen-containing spiroheterocycle, and a 7-9 membered nitrogen-containing spiroheterocycle. Specific examples include but are not limited to: wait.

[0156] The term "bridged heterocyclic group" refers to a cyclic structure derived from a "bridged heterocyclic group" in which at least one carbon atom is replaced by a heteroatom / heteroatom group, wherein the heteroatom / heteroatom group is selected from N, O, S, P, NO, SO, S(O)2, P(O) and NR, R is H or any substituent group that may exist, and the "bridged cycloalkyl" is as defined above. The bridged heterocycle is preferably a "nitrogen-containing bridged heterocycle", which refers to a heterocycle in which at least one ring atom is NR. The bridged heterocycle includes "7- to 11-membered bridged heterocycle", "6- to 10-membered bridged heterocycle", "6- to 8-membered bridged heterocycle", etc., and the connection site with the parent is not limited. Specific examples include, but are not limited to: wait.

[0157] The term "aryl" refers to a monocyclic all-carbon aromatic ring (i.e., a monocyclic aromatic group) or a polycyclic aromatic ring system (i.e., a polycyclic aromatic group) having a conjugated π electron system, which has 6 to 14 (e.g., 6, 7, 8, 9, 10, 11, 12, 13 or 14) ring atoms (i.e., a 6- to 14-membered aromatic group). The aryl group is preferably an aromatic group having 6 to 10 ring atoms (i.e., a 6- to 10-membered aromatic group). The monocyclic aromatic group is, for example, a phenyl group. Non-limiting examples of the polycyclic aromatic group include: naphthyl, anthracenyl, phenanthrenyl, etc. The polycyclic aromatic group also includes a phenyl group fused with one or more heterocyclic groups or cycloalkyl groups, or a naphthyl group fused with one or more heterocyclic groups or cycloalkyl groups, wherein the connection point is on the phenyl group or naphthyl group, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic aromatic ring system, non-limiting examples include:

[0158] wait.

[0159] The term "heteroaryl" refers to a monocyclic heteroaromatic ring (i.e., a monocyclic heteroaryl) or a polycyclic heteroaromatic ring system (i.e., a polycyclic heteroaryl) having a conjugated π electron system, which contains at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS-, or -SS-), and has 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (i.e., a 5- to 14-membered heteroaryl). The heteroaryl is preferably a heteroaryl having 5 to 10 ring atoms (i.e., a 5- to 10-membered heteroaryl), more preferably a heteroaryl having 5 or 6 ring atoms (i.e., a 5- or 6-membered heteroaryl). The polycyclic heteroaryl group preferably has 6 to 14 (eg, 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (ie, a 6- to 14-membered fused heteroaryl group).

[0160] The monocyclic heteroaryl groups include, but are not limited to, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furazanyl, pyrrolyl, N-alkylpyrrolyl, pyridyl, pyrimidinyl, pyridonyl, N-alkylpyridone (e.g. etc.), pyrazinyl, pyridazinyl, etc.

[0161] The polycyclic heteroaryl groups include, but are not limited to, indolyl, indazolyl, quinolyl, isoquinolyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophenyl, quinazolinyl, benzothiazolyl, carbazolyl, and the like. The polycyclic heteroaryl groups also include monocyclic heteroaryl groups fused to one or more aromatic groups, wherein the point of attachment is on the aromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. The polycyclic heteroaryl groups also include monocyclic heteroaryl groups fused to one or more cycloalkyl or heterocyclic groups, wherein the point of attachment is on the monocyclic heteroaromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. Non-limiting examples include:

[0162]

[0163] wait.

[0164] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0165] The term "hydroxy" refers to -OH.

[0166] The term "amino" refers to -NH2.

[0167] It should be known to those skilled in the art that the linker L disclosed in the present disclosure or its corresponding specific structure is connected to Ab via a sulfur atom from Ab, and the sulfur atom S can be reflected in the structural formula or chemical formula of L or L1, or can be omitted, hidden or not reflected. Can also be written as Both represent the same structure and meaning; It can also be written as Can be written as The same understanding can be applied to other L1 segments.

[0168] The term "warhead drug molecule," also known as "payload," "drug payload," or "payload," refers to a substance that has the potential to prevent or treat disease. The drug in an antibody-drug conjugate is typically a cytotoxic drug, a chemical molecule that has the potential to disrupt the normal growth of tumor cells.

[0169] The term "linker" refers to a chemical structure fragment or bond that is connected to a ligand at one end and to a drug at the other end. It can also be connected to other linkers before being connected to the drug.

[0170] The term "drug-linker conjugate" is also referred to as payload-linker conjugate, linker-payload conjugate, and has the same meaning in the present disclosure.

[0171] The disclosed compounds may exist in specific stereoisomeric forms. The term "stereoisomer" refers to isomers having identical structures but different arrangements of atoms in space. It includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers, (D)- and (L)-isomers, tautomers, atropisomers, conformers and mixtures thereof (such as racemates, mixtures of diastereomers). The substituents in the disclosed compounds may have additional asymmetric atoms. All of these stereoisomers and their mixtures are included within the scope of the present disclosure. Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers and (D)- and (L)-isomers can be prepared by chiral synthesis, chiral reagents or other conventional techniques. An isomer of a compound disclosed herein can be prepared by asymmetric synthesis or chiral auxiliary, or, when the molecule contains a basic functional group (e.g., amino) or an acidic functional group (e.g., carboxyl), by forming a diastereomeric salt with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art to obtain the pure isomer. Furthermore, separation of enantiomers and diastereomers is typically accomplished by chromatography.

[0172] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if chiral isomers exist in the chemical structure, the bond Can be or or include both and For all carbon-carbon double bonds, even if only one configuration is named, both the Z and E configurations are included.

[0173] When a substituent's bond can cross-link to a ring, it means that the substituent can be bonded to any atom on the ring. Represents the substituent R 4 Substitution can occur at any position on ring A (including NH), and R 4 The number of is n.

[0174] When any variable (such as R 4 ) occurs more than once in the composition or structure of a compound, its definition in each instance is independent. For example, a structural unit Indicates that ring A is surrounded by n R 4 is replaced, and each R 4 There are independent options.

[0175] When a substituent is listed without specifying the atom through which the substituent is attached to a given group or a given structural formula, the substituent may be attached via any bondable atom. For example, pyrimidine as a substituent means that any carbon atom or nitrogen atom on the pyrimidine ring is attached to the substituted group. For example, in the present disclosure, ring A is selected from There is no limitation on the connection site in the structural unit, which means that any atom on the azetidine ring can be connected to a given group or a given structural formula.

[0176] The presence of a dash "-" in a substituent structure indicates the point of attachment for the substituent, for example -CH3 is attached through a C atom.

[0177] Specifically, all combinations of substituents and / or variations thereof are permissible only if such combinations result in stable compounds.

[0178] The compounds of the present disclosure include all suitable isotopically labeled compounds thereof. The term "isotopically labeled" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that can be introduced into the compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, for example, 2 H (deuterium, D), 3 H (tritium, T), 11 C. 13C. 14 C. 15 N. 17 O. 18 O. 32 p、 33 p、 33 S. 34 S. 35 S. 36 S. 18 F. 36 Cl, 82 Br, 123 I. 124 I. 125 I. 129 I and 131 I, etc., preferably deuterium.

[0179] Compared to non-deuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and prolonged biological half-life. All isotopic variations of the compounds disclosed herein, whether radioactive or not, are encompassed by the present disclosure. Each available hydrogen atom attached to a carbon atom can be independently replaced with a deuterium atom, where the deuterium replacement can be partial or complete. Partial deuterium replacement refers to the replacement of at least one hydrogen atom with at least one deuterium atom.

[0180] The preparation methods of some compounds disclosed herein refer to the preparation methods of the aforementioned similar compounds. Those skilled in the art should be aware that when using or referring to the preparation methods cited, the feed ratio of reactants, reaction solvent, reaction temperature, etc. can be appropriately adjusted according to the different reactants.

[0181] The compounds disclosed herein can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include, but are not limited to, the examples disclosed herein.

[0182] Unless otherwise specified, the “compound of the present disclosure” includes the payload compound and ADC compound described in the present disclosure.

[0183] "Substitution" or "substituted" means that one or more hydrogen atoms, preferably 1 to 6, more preferably 1 to 3 hydrogen atoms, in a group are independently replaced by a corresponding number of substituents. Those skilled in the art will be able to determine (by experiment or theory) whether substitution is possible or not without undue effort. For example, an amino or hydroxyl group having free hydrogens may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.

[0184] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.

[0185] The term "pharmaceutically acceptable salt" refers to derivatives of the disclosed compounds prepared with relatively nontoxic acids or bases. These salts can be prepared during compound synthesis, isolation, and purification, or by reacting the purified free form of the compound with a suitable acid or base. When the compound contains relatively acidic functional groups, base addition salts are obtained by reaction with alkali metal or alkaline earth metal hydroxides or organic amines. These salts include cations based on alkali and alkaline earth metals, as well as nontoxic ammonium, quaternary ammonium, and amine cations, and also encompass salts of amino acids. When the compound contains relatively basic functional groups, acid addition salts are obtained by reaction with organic or inorganic acids.

[0186] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0187] The term "pharmaceutically acceptable carrier" refers to a medium generally accepted in the art for delivering biologically active agents to animals, particularly mammals, and includes, for example, adjuvants, excipients, or vehicles, such as diluents, preservatives, fillers, flow regulators, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, fragrances, antibacterial agents, antifungal agents, lubricants, and dispersants, depending on the mode of administration and the nature of the dosage form. Pharmaceutically acceptable carriers are formulated within the purview of those skilled in the art based on a wide range of factors. These include, but are not limited to, the type and nature of the active agent being formulated, the subject to whom the composition containing the agent is to be administered, the intended route of administration of the composition, and the intended therapeutic indication. Pharmaceutically acceptable carriers include both aqueous and non-aqueous media, as well as a variety of solid and semisolid dosage forms. In addition to the active agent, such carriers include a variety of different ingredients and additives, and the inclusion of such additional ingredients in a formulation for various reasons (e.g., to stabilize the active agent, binders, etc.) is well known to those skilled in the art.

[0188] The term "therapeutically effective amount" refers to a sufficient amount of a compound of the present disclosure, its pharmaceutically acceptable salt, or its stereoisomer to treat a disorder at a reasonable benefit / risk ratio applicable to any medical treatment and / or prevention. However, it should be understood that the total daily dosage of all formulae described herein, including but not limited to formula (I), formula (II), and the compounds shown in Table 2, their stereoisomers, or their pharmaceutically acceptable salts, and compositions, must be determined by the attending physician within the scope of sound medical judgment. For any particular patient, the specific therapeutically effective dosage level must be determined based on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific compound being used; the specific composition being used; the patient's age, weight, general health, sex, and diet; the administration time, route of administration, and excretion rate of the specific compound being used; the duration of treatment; drugs used in combination with or concurrently with the specific compound being used; and similar factors known in the medical field. With respect to drugs or pharmacologically active agents, the term "therapeutically effective amount" refers to a sufficient amount of a drug or agent that is non-toxic but can achieve the desired effect. The determination of the effective amount varies from person to person, depends on the age and general condition of the recipient, and also depends on the specific active substance. The appropriate effective amount in each case can be determined by a person skilled in the art based on routine experiments.

[0189] As used herein, the singular form "a," "an," and "the" include plural references and vice versa unless the context clearly dictates otherwise.

[0190] When the term "about" is applied to a parameter such as pH, concentration, temperature, etc., it indicates that the parameter can vary by ±10%, and sometimes more preferably within ±5%. As will be understood by those skilled in the art, when a parameter is not critical, numbers are generally given for illustration purposes only and are not limiting. DETAILED DESCRIPTION

[0191] The present disclosure is described in detail below by way of examples, but is not intended to limit the present disclosure in any way. While the present disclosure has been described in detail herein, including specific embodiments thereof, it will be apparent to those skilled in the art that various changes and modifications may be made to the specific embodiments of the present disclosure without departing from the spirit and scope of the invention.

[0192] In the embodiments of the present disclosure, the naming of the compounds is converted from the compound structure with the help of Chemdraw. If there is an inconsistency between the compound name and the compound structure, it can be determined by integrating relevant information and reaction routes. The preparation methods of some compounds in the present disclosure quote the preparation methods of the aforementioned similar compounds. Those skilled in the art should know that when using or referring to the preparation methods cited, the feed ratio of the reactants, the reaction solvent, the reaction temperature, etc. can be appropriately adjusted according to the different reactants. The compounds of the present disclosure can be prepared by a variety of synthesis methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and equivalent replacement methods well known to those skilled in the art. Preferred embodiments include but are not limited to the embodiments of the present disclosure.

[0193] It will be clear to those skilled in the art that, hereinafter, unless otherwise specified, the materials used are well known in the art and can be purchased commercially or obtained by those skilled in the art according to published literature or conventional methods. Unless otherwise specified, all reactions disclosed herein are carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere, and the solvent is a dry solvent, wherein: (i) the temperature is expressed in degrees Celsius (°C), and the operation is carried out at room temperature, which generally refers to 15-35°C, preferably 20-30°C, and more preferably 20-25°C; (ii) the solvent is removed by evaporation under reduced pressure on a rotary evaporator with a bath temperature not higher than 60°C; (iii) the reaction process is tracked by thin layer chromatography (TLC); (iv) the final product has satisfactory hydrogen nuclear magnetic resonance spectroscopy (1H-NMR) and / or mass spectrometry (MS) data.

[0194] 1. Summary of experimental instruments

[0195] The structures of the compounds disclosed herein are confirmed by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS).

[0196] NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements were performed using a Bruker Neo400M or Bruker Ascend 400 NMR instrument. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD), and / or deuterated chloroform (CDCl3), with tetramethylsilane (TMS) as the internal standard.

[0197] Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 1260-6125B single quadrupole mass spectrometer, and HPLC was performed using an Agilent 1260 high performance liquid chromatograph.

[0198] Preparative high performance liquid chromatography used Shimadzu FRC-40 equipped with LC-20AP and PDA-20A (chromatographic column: Synergi Max-RP, 150×30 mm, 4 m) or GILSON GX-281LC (chromatographic columns: Boston Prime C18 150*30 mm*5 μm; YMC-Actus Triart C18 150*30 mm*5 μm; YMC-Triart PFP 150*30 mm*5 μm; YMC-Triart Phenyl 150*30 mm*5 μm).

[0199] The preparation and separation conditions of all the compounds in the examples are as follows: (Chromatographic column: Boston Prime C18 150*30mm*5μm; A: 0.225% FA in Waters; B: MeCN)

[0200] The reaction progress in the examples can be monitored by conventional methods such as thin layer chromatography (TLC) and LC-MS. The eluent system for column chromatography and the developing solvent system for thin layer chromatography used for purification can be composed of one or more of the following solvents: dichloromethane, methanol, n-hexane, ethyl acetate, petroleum ether, ethyl acetate, acetone, dichloromethane, etc. The volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine, acetic acid, trifluoroformic acid, etc. can also be added for adjustment.

[0201] The abbreviations and their corresponding chemical names used in the embodiments of the present disclosure are as follows:

[0202] TBDPSCl: tert-butyldiphenylchlorosilane

[0203] EtOAc: ethyl acetate

[0204] MeOH: methanol

[0205] THF: Tetrahydrofuran

[0206] TBAF: Tetrabutylammonium fluoride

[0207] PABA: para-aminobenzoic acid

[0208] EEDQ: 2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline

[0209] DIEA: N,N-diisopropylethylamine

[0210] DMF: N,N-dimethylformamide

[0211] DCM: dichloromethane

[0212] DMSO: dimethyl sulfoxide

[0213] Trastuzumab used in this disclosure was purchased from Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. The antibody sequence is as follows:

[0214] The amino acid sequence of the light chain is shown in SEQ ID NO: 1:

[0215] DIQMTQSPSSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSAS

[0216] FLYSGVPS

[0217] RFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAP

[0218] SVFIFPP

[0219] SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD

[0220] STYSLSSTLT

[0221] LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0222] The amino acid sequence of the heavy chain is shown in SEQ ID NO: 2:

[0223] EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARI

[0224] YPTNGYTRY

[0225] ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDY

[0226] WGQGTLVTVSS

[0227] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT

[0228] FPAVLQSS

[0229] GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC

[0230] PAPELLGG

[0231] PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK

[0232] TKPREEQYN

[0233] STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV

[0234] YTLPPSREE

[0235] MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS

[0236] KLTVDKSRW

[0237] QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0238] 2. Synthesis Example

[0239] Compound A-1 in the following synthesis examples is compound Eribulin-N3 (ER-076349), which can be prepared according to WO9965894:

[0240]

[0241] Compound A-2 is the compound Eribulin, which can be prepared according to WO9965894:

[0242]

[0243] Specific synthesis:

[0244] Example 1

[0245]

[0246] The synthetic route is as follows:

[0247]

[0248] Step 1: Synthesis of compound 1-1

[0249] Compound A-1 (100 mg, 0.137 mM) was added to a 10 mL single-necked vial and dissolved in dichloromethane (5 mL). To the resulting solution were added p-toluenesulfonic anhydride (49.12 mg, 0.151 mM), pyridine (0.011 mL, 0.137 mM), and 2,4,6-trimethylpyridine (66.32 mg, 0.547 mM). The reaction mixture was stirred at room temperature overnight. LCMS monitoring indicated a 60% reaction. The reaction mixture was concentrated under reduced pressure to yield crude product 1-1 (121.26 mg, 100.08% yield).

[0250] LC-MS:885.4[M+H] +

[0251] Step 2: Synthesis of compound 1-2

[0252] To a 100 mL single-necked vial was added tert-butyl (1R,4R)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (1000.00 mg, 5.044 mM) and dissolved in N,N-dimethylformamide (10 mL). To the resulting solution were added 9-fluorenylmethyl-N-succinimidyl carbonate (1871.64 mg, 5.548 mM) and triethylamine (1.402 mL, 10.088 mM). The reaction was stirred at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in dichloromethane and washed twice with 1 M hydrochloric acid and water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield compound 1-2 (2121.05 mg, 100.07% yield).

[0253] LC-MS:421.2[M+H] +

[0254] Step 3: Synthesis of Compound 1-3

[0255] Compound 1-2 (2121.05 mg, 5.044 mM) was added to a 100 mL single-necked vial and dissolved in dichloromethane (5 mL). Dioxane hydrochloride (12.610 mL) was added to the resulting solution. The reaction was stirred overnight at room temperature. LCMS monitored the reaction for completion. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in dichloromethane, washed with water and sodium bicarbonate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield compound 1-3 (1616.05 mg, 100.06% yield).

[0256] LC-MS: 321.2[M+H] +

[0257] Step 4: Synthesis of compound 1

[0258] Compound 1-1 (72.58 mg, 0.082 mM) and compound 1-3 (78.82 mg, 0.246 mM) were added to a 25 mL single-necked vial and dissolved in methanol (10 mL). Triethylamine (0.046 mL) was added to the resulting solution. The reaction mixture was stirred at 60°C overnight. LCMS confirmed the reaction was complete. The reaction mixture was concentrated under reduced pressure, and the residue was purified to obtain compound 1 (5 mg, yield: 7.52%).

[0259] LC-MS: 810.6[M+H] +

[0260] Example 2

[0261]

[0262] The synthetic route is as follows:

[0263]

[0264] Referring to the preparation method of compound 1, compound 2 (5.2 mg, yield: 15%) was prepared from compound 2,6-diaza-spiro[3.4]octane-2-carbonate tert-butyl ester as the starting material.

[0265] LC-MS: 825.4[M+H] +

[0266] Example 3

[0267]

[0268] The synthetic route is as follows:

[0269]

[0270] Referring to the preparation method of compound 1, compound 3 (5.6 mg, yield: 9%) was prepared from compound 2,6-diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester as the starting material.

[0271] LC-MS: 811.4[M+H] +

[0272] Example 5

[0273]

[0274] The synthetic route is as follows:

[0275]

[0276] Compound 1-1 (48.68 mg, 0.055 mM) and 3-hydroxyazetidine hydrochloride (20.39 mg, 0.165 mM) were added to a 25 mL single-necked vial and dissolved in methanol (10 mL). Triethylamine (0.031 mL) was added to the resulting solution. The reaction was stirred at 60°C overnight. LCMS confirmed the reaction was complete. The reaction solution was concentrated under reduced pressure, and the residue was purified to yield compound 5 (3.9 mg, 9.03% yield).

[0277] LC-MS:786.4[M+H] +

[0278] Example 6

[0279]

[0280] The synthetic route is as follows:

[0281]

[0282] Referring to the preparation method of compound 5, compound 6 (3.7 mg, yield: 9.12%) was prepared from azetidin-3-ylmethanol as the starting material.

[0283] LC-MS: 800.6[M+H] +

[0284] Example 7

[0285]

[0286] The synthetic route is as follows:

[0287]

[0288] Referring to the preparation method of compound 5, compound 7 (5.7 mg, yield: 11.32%) was prepared from compound 2-hydroxy-1-(piperazin-1-yl)ethanone as the starting material.

[0289] LC-MS:857.3[M+H] +

[0290] Example 8

[0291]

[0292] The synthetic route is as follows:

[0293]

[0294] Referring to the synthesis method of compound 5, compound 8 (6.7 mg, yield: 14.22%) was prepared from compound 2-oxa-6-aza-spiro[3,3]heptane as the starting material.

[0295] LC-MS: 812.4[M+H] +

[0296] Example 14

[0297]

[0298] The synthetic route is as follows:

[0299]

[0300] Step 1: Synthesis of compound 14-1

[0301] Fmoc-glycine (120 mg, 0.4 mM), PABA (50 mg, 0.4 mM) and EEDQ (152 mg, 0.6 mM) were added to a 100 mL single-necked bottle, dissolved in THF (10 mL), and reacted at room temperature overnight. The reaction solution was concentrated under reduced pressure, and the residue was slurried with tert-methyl ether to obtain compound 14-1 (152 mg, yield: 94.48%).

[0302] LC-MS:403.2[M+H] +

[0303] Step 2: Synthesis of compound 14-2

[0304] Compound 14-1 (100 mg, 0.25 mM) and di(p-nitrobenzene) carbonate (304 mg, 1 mM) were added to a 25 mL single-necked vial and dissolved in N,N-dimethylformamide (5 mL). DIEA (174 μL, 1 mM) was added to the solution, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 14-2 (75.2 mg, 53.03% yield).

[0305] LC-MS: 568.2[M+H] +

[0306] Step 3: Synthesis of compound 14-3

[0307] Compound 14-2 (22.68 mg, 0.04 mM) and compound A-2 (14.58 mg, 0.02 mM) were added to a 25 mL single-necked vial and dissolved in N,N-dimethylformamide (5 mL). DIEA (18 μL, 0.1 mM) was added to the solution, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 14-3 (15.2 mg, 65.65% yield).

[0308] LC-MS: 1158.6[M+H] +

[0309] Step 4: Synthesis of compound 14

[0310] To a 10 mL single-necked vial, 14-3 (15.2 mg, 0.013 mM) was added and dissolved in N,N-dimethylformamide (3 mL). Diethylamine (0.0128 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was purified to obtain compound 14 (9.2 mg, 75.65% yield).

[0311] LC-MS:936.4[M+H] +

[0312] Example 17

[0313]

[0314] The synthetic route is as follows:

[0315]

[0316] Step 1: Synthesis of compound 17-1

[0317] 15-1 (47.57 mg, 0.05 mM) and [[2-(FMOC-amino)acetamido]methyl]acetate (3.68 mg, 0.01 mM) were added to a 25 mL single-necked vial and dissolved in DCM (5 mL). TFA (20 μL) was added to the solution, and the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography to afford 17-1 (12.59 mg, 20%).

[0318] LC-MS: 1260.6[M+H] +

[0319] Step 2: Synthesis of compound 17

[0320] To a 10 mL single-necked vial, 17-1 (12 mg, 0.0095 mM) was added and dissolved in DMF (5 mL). Diethylamine (0.0188 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was purified to obtain compound 17 (5.2 mg, 67.28% yield).

[0321] LC-MS: 816.4[M+H] +

[0322] Example 18

[0323]

[0324] The synthetic route is as follows:

[0325]

[0326] Step 1: Synthesis of compound 18-1

[0327] In a 25 mL single-necked vial, 15-1 (47.57 mg, 0.05 mM) and di(p-nitrobenzene) carbonate (61 mg, 0.2 mM) were added and dissolved in N,N-dimethylformamide (5 mL). DIEA (37 μL) was added to the solution, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 18-1 (35.2 mg, 63.06% yield).

[0328] LC-MS: 1117.5[M+H] +

[0329] Step 2: Synthesis of compound 18-2

[0330] Fmoc-glycine (96 mg, 0.32 mM), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (92.8 mg, 0.32 mM), and 1-hydroxybenzotriazole (4.05 mg, 0.03 mM) were added to a 10 mL single-necked vial and dissolved in N,N-dimethylformamide (5 mL). Diisopropylethylamine (0.32 mL) was added to the resulting solution, and the mixture was stirred at room temperature for 15 minutes. N-Boc-N-methylethylenediamine (41.8 mg, 0.24 mM) was then added to the mixture. The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was filtered and purified to obtain compound 18-2 (58.2 mg, 53.51% yield).

[0331] LC-MS:454.2[M+H] +

[0332] Step 3: Synthesis of compound 18-3

[0333] Compound 18-2 (45.4 mg, 0.1 mM) was added to a 100 mL single-necked vial and dissolved in dichloromethane (5 mL). A dioxane hydrochloride solution (1 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight. LCMS confirmed the reaction was complete. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in dichloromethane, washed with water and sodium bicarbonate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford compound 18-3 (31.22 mg, 88.40% yield).

[0334] LC-MS: 354.2[M+H] +

[0335] Step 4: Synthesis of compound 18-4

[0336] In a 25 mL single-necked vial, 18-3 (5.3 mg, 0.015 mM) and compound 18-1 (33.49 mg, 0.03 mM) were added and dissolved in N,N-dimethylformamide (5 mL). DIEA (13.5 μL) was added to the solution, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 18-4 (9.2 mg, 46.09% yield).

[0337] LC-MS: 1331.7[M+H] +

[0338] Step 5: Synthesis of compound 18

[0339] To a 10 mL single-necked vial, 18-4 (9.2 mg, 0.0069 mM) was added and dissolved in DMF (5 mL). Diethylamine (0.0137 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was purified to obtain compound 18 (3.2 mg, 52.31% yield).

[0340] LC-MS:887.4[M+H] +

[0341] Linker-Payload Synthesis Example

[0342] Example B1

[0343]

[0344] The synthetic route is as follows:

[0345]

[0346] Step 1: Synthesis of Compound B1-2

[0347] Compound B1-1 (500.0 mg, 2.68 mmol) was added to a 25 mL single-necked flask and dissolved in DMF (10 mL). Hydroxyacetic acid (244.9 mg, 3.22 mmol), HATU (1224.3 mg, 3.22 mmol), and DIPEA (1.4 mL, 8.04 mmol) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was purified by column chromatography to afford product B1-2 (590.2 mg, 90% yield).

[0348] LC-MS: 245.2[M+H] +

[0349] Step 2: Synthesis of Compound B1-4

[0350] Compound B1-3 (300.0 mg, 0.81 mmol) was added to a 50 mL single-necked flask and dissolved in toluene (8 mL). Compound B1-2 (397.8 mg, 1.63 mmol) and zinc acetate (297.4 mg, 1.63 mmol) were added to the resulting solution. The reaction mixture was stirred under reflux overnight and then concentrated under reduced pressure. The residue was purified by column chromatography to afford product B1-4 (135.2 mg, 30% yield).

[0351] LC-MS: 553.6[M+H] +

[0352] Step 3: Synthesis of Compound B1-5

[0353] Compound B1-4 (500.0 mg, 0.90 mmol) was added to a 25 mL single-necked vial and dissolved in DCM (9 mL). Diethylamine (1.86 mL, 18 mmol) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to obtain the crude product B1-5 (300.0 mg, 100.6% yield).

[0354] LC-MS: 330.3[M+H] +

[0355] Step 4: Synthesis of Compound B1-6

[0356] Compound B1-5 (220 mg, 0.66 mmol) was added to a 50 mL single-necked flask and dissolved in DMF (5 mL). Fmoc-Gly-Gly-Phe-OH (400.7 mg, 0.79 mmol), HATU (300.3 mg, 0.79 mmol), and DIPEA (0.35 mL, 2 mmol) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography to afford product B1-6 (432.2 mg, 80% yield).

[0357] LC-MS: 814.9 [M+H] +

[0358] Step 5: Synthesis of Compound B1-7

[0359] Compound B1-6 (500.0 mg, 2.68 mmol) was added to a 50 mL single-necked vial and dissolved in DCM (10 mL). Diethylamine (5.6 mL, 53.6 mmol) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to obtain the crude product B1-7 (363.4 mg, 100% yield).

[0360] LC-MS: 592.6[M+H] +

[0361] Step 6: Synthesis of Compound B1-9

[0362] Compound B1-7 (200.0 mg, 0.33 mmol) was added to a 50 mL single-necked vial and dissolved in DMF (10 mL). Compound B1-8 (104.3 mg, 0.40 mmol), HATU (152.1 mg, 0.4 mmol), and DIPEA (0.18 mL, 1.01 mmol) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography to afford product B1-8 (168.2 mg, 60% yield).

[0363] LC-MS:831.8[M+H] +

[0364] Step 7: Synthesis of Compound B1-10

[0365] Compound B1-9 (50.0 mg, 0.06 mmol) was added to a 50 mL single-necked vial and dissolved in DCM (3 mL). TFA (0.6 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to afford product B1-10 (39.5 mg, 90% yield).

[0366] LC-MS:731.7[M+H] +

[0367] Step 8: Synthesis of Compound B1

[0368] Compound 1-1 (45.0 mg, 0.051 mmol) and compound B1-10 (111.4 mg, 0.15 mmol) were added to a 25 mL single-necked flask and dissolved in methanol (10 mL). Triethylamine (0.004 mL) was added to the resulting solution. The reaction mixture was stirred at 60°C overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified to obtain compound B1 (7.8 mg, 8.0% yield).

[0369] LC-MS: 1444.6[M+H] +

[0370] Example B2

[0371]

[0372] The synthetic route is as follows:

[0373]

[0374] Step 1: Synthesis of compound B2-2

[0375] Compound B2-1 (500.0 mg, 1.31 mmol) was added to a 50 mL single-necked flask and dissolved in toluene (8 mL). Compound B1-2 (638.8 mg, 2.61 mmol) and zinc acetate (478.8 mg, 2.61 mmol) were added to the resulting solution. The reaction mixture was stirred under reflux overnight and then concentrated under reduced pressure. The residue was purified by column chromatography to afford product B2-2 (222.2 mg, 30% yield).

[0376] LC-MS: 567.6[M+H] +

[0377] Step 2: Synthesis of Compound B2-3

[0378] Compound B1-4 (300.0 mg, 0.53 mmol) was added to a 50 mL single-necked vial and dissolved in DCM (9 mL). Diethylamine (1.1 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to obtain the crude product B2-3 (183.4.0 mg, 100.6% yield).

[0379] LC-MS: 345.3[M+H] +

[0380] Step 3: Synthesis of Compound B2-4

[0381] Compound B2-3 (220 mg, 0.66 mmol) and Fmoc-valine (354.7 mg, 1.05 mmol) were added to a 50 mL single-necked bottle and dissolved in DMF (6 mL). HATU (300.3 mg, 0.79 mmol) and DIPEA (0.47 mL) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was purified by column chromatography to afford product B2-4 (464.1 mg, 80% yield).

[0382] LC-MS: 666.8[M+H] +

[0383] Step 4: Synthesis of Compound B2-5

[0384] Compound B2-4 (300.0 mg, 0.45 mmol) was added to a 50 mL single-necked vial and dissolved in DCM (10 mL). Diethylamine (0.9 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to obtain the crude product B2-5 (201.4 mg, 100.8% yield).

[0385] LC-MS:444.5[M+H] +

[0386] Step 5: Synthesis of Compound B2-7

[0387] Compounds B2-5 (300.0 mg, 0.67 mmol) and B2-6 (272.9 mg, 0.81 mmol) were added to a 50 mL single-necked bottle and dissolved in DMF (7 mL). HATU (307.9 mg, 0.81 mmol) and DIPEA (0.36 mL, 2.03 mmol) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was purified by column chromatography to afford product B2-7 (307.2 mg, 60% yield).

[0388] LC-MS:762.8[M+H] +

[0389] Step 6: Synthesis of Compound B2-8

[0390] Compound B2-7 (350.0 mg, 0.46 mmol) was added to a 50 mL single-necked vial and dissolved in DCM (5 mL). TFA (1 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to afford product B2-8 (39.5 mg, 90% yield).

[0391] LC-MS: 662.7[M+H] +

[0392] Step 7: Synthesis of Compound B2

[0393] Compound 1-1 (30.0 mg, 0.033 mmol) and compound B2-8 (67.2 mg, 0.10 mmol) were added to a 25 mL single-necked flask and dissolved in methanol (2 mL). Triethylamine (0.003 mL) was added to the resulting solution. The reaction mixture was stirred at 60°C overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified to obtain compound B2 (3.7 mg, 8.0% yield).

[0394] LC-MS: 1375.6[M+H] +

[0395] Example B3

[0396]

[0397] Referring to the preparation method of compound B1, compound B3 (7.7 mg, yield: 9.12%) was obtained by purification via liquid preparative chromatography.

[0398] LC-MS: 1523.7[M+H] +

[0399] Example B4

[0400]

[0401] Referring to the preparation method of compound B2, compound B4 (5.9 mg, yield: 8.12%) was obtained by purification via liquid preparative chromatography.

[0402] LC-MS: 1309.5[M+H] +

[0403] Example B5

[0404]

[0405] Referring to the preparation method of compound B1, compound B5 (7.0 mg, yield: 8.52%) was obtained by purification via liquid preparative chromatography.

[0406] LC-MS: 1457.6[M+H] +

[0407] Example B6

[0408]

[0409] The synthetic route is as follows:

[0410]

[0411] Step 1: Synthesis of compound B6-2

[0412] Compounds B6-1 (455.6 mg, 0.61 mmol) and B1-7 (300 mg, 0.51 mmol) were added to a 50 mL single-necked bottle and dissolved in DMF (10 mL). HATU (231.9 mg, 0.61 mmol) and DIPEA (0.27 mL) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight, then concentrated under reduced pressure and purified by column chromatography to yield product B6-2 (543.1 mg, 81% yield).

[0413] LC-MS: 1323.5[M+H] +

[0414] Step 2: Synthesis of compound B6-3

[0415] Compound B6-2 (400.0 mg, 0.3 mmol) was added to a 50 mL single-necked vial and dissolved in DCM (10 mL). Diethylamine (0.61 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to obtain the crude product B6-3 (333.4 mg, 100% yield).

[0416] LC-MS: 1101.3 [M+H] +

[0417] Step 3: Synthesis of compound B6-4

[0418] Compounds B6-3 (200.0 mg, 0.18 mmol) and B4-1 (63.8 mg, 0.24 mmol) were added to a 50 mL single-necked bottle and dissolved in DMF (5 mL). HATU (152.1 mg, 0.4 mmol) and DIPEA (0.095 mL) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was purified by column chromatography to afford product B6-4 (159.7 mg, 65% yield).

[0419] LC-MS: 1353.5[M+H] +

[0420] Step 4: Synthesis of compound B6-5

[0421] Compound B6-4 (40.0 mg, 0.029 mmol) was added to a 50 mL single-necked vial and dissolved in DCM (3 mL). TFA (0.6 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to afford product B6-5 (33.3 mg, 90% yield).

[0422] LC-MS: 1253.4[M+H] +

[0423] Step 5: Synthesis of Compound B6

[0424] Compound 1-1 (50.0 mg, 0.056 mmol) and compound B6-5 (212.2 mg, 0.17 mmol) were added to a 25 mL single-necked flask and dissolved in methanol (5 mL). Triethylamine (0.004 mL) was added to the resulting solution. The reaction mixture was stirred at 60°C overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified to obtain compound B6 (8.6 mg, yield: 7.8%).

[0425] LC-MS: 983.66 [M / 2+H] +

[0426] Example B7

[0427]

[0428] The synthetic route is as follows:

[0429]

[0430] Step 1: Synthesis of compound B7-1

[0431] Compounds B1-7 (500.0 mg, 1.13 mmol) and B6-1 (1010 mg, 1.35 mmol) were added to a 50 mL single-necked vial and dissolved in DMF (10 mL). HATU (513.3 mg, 1.35 mmol) and DIPEA (0.61 mL) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight, then concentrated under reduced pressure and purified by column chromatography to yield product B7-1 (541.1 mg, 81% yield).

[0432] LC-MS: 1175.4[M+H] +

[0433] Step 2: Synthesis of compound B7-2

[0434] Compound B7-1 (300.0 mg, 0.25 mmol) was added to a 50 mL single-necked flask and dissolved in DCM (10 mL). Diethylamine (0.52 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to obtain crude product B7-2 (245.4 mg, 100.8% yield).

[0435] LC-MS:953.1[M+H] +

[0436] Step 3: Synthesis of compound B7-4

[0437] Compounds B7-2 (200.0 mg, 0.21 mmol) and B7-3 (162.9 mg, 0.25 mmol) were added to a 50 mL single-necked bottle and dissolved in DMF (5 mL). HATU (95.1 mg, 0.25 mmol) and DIPEA (0.11 mL) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was purified by column chromatography to afford product B7-4 (196.3 mg, 65% yield).

[0438] LC-MS: 1438.6[M+H] +

[0439] Step 4: Synthesis of compound B7-5

[0440] Compound B7-4 (40.0 mg, 0.028 mmol) was added to a 50 mL single-necked vial and dissolved in DCM (3 mL). TFA (0.6 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to afford product B7-5 (33.7 mg, 90% yield).

[0441] LC-MS: 1338.5[M+H] +

[0442] Step 5: Synthesis of Compound B7

[0443] Compound 1-1 (50.0 mg, 0.056 mmol) and compound B7-5 (226.7 mg, 0.17 mmol) were added to a 25 mL single-necked flask and dissolved in methanol (5 mL). Triethylamine (0.005 mL) was added to the resulting solution. The reaction mixture was stirred at 60°C overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified to obtain compound B7 (9.0 mg, yield: 7.8%).

[0444] LC-MS: 1026.2[M / 2+H] +

[0445] Example B8

[0446]

[0447] Referring to the preparation method of compound B7, compound B8 (9.3 mg, yield: 7.5%) was obtained by purification via liquid preparative chromatography.

[0448] LC-MS: 1100.2 [M / 2+H] +

[0449] Example B9

[0450]

[0451] The synthetic route is as follows:

[0452]

[0453] Step 1: Synthesis of compound B9-2

[0454] Compounds B6-3 (350.0 mg, 0.59 mmol) and B9-1 (336.1 mg, 0.71 mmol) were added to a 50 mL single-necked bottle and dissolved in DMF (6 mL). HATU (513.3 mg, 0.71 mmol) and DIPEA (0.32 mL) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight, then concentrated under reduced pressure and purified by column chromatography to yield product B7-1 (526.1 mg, 85% yield).

[0455] LC-MS: 1048.2[M+H] +

[0456] Step 2: Synthesis of compound B9-3

[0457] Compound B9-2 (300.0 mg, 0.28 mmol) was added to a 50 mL single-necked flask and dissolved in DCM (10 mL). Diethylamine (0.56 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to obtain the crude product B9-3 (270.4 mg, 102.8% yield).

[0458] LC-MS:825.9[M+H] +

[0459] Step 3: Synthesis of compound B9-4

[0460] Compounds B9-3 (200.0 mg, 0.24 mmol) and B6-1 (217.8 mg, 0.29 mmol) were added to a 50 mL single-necked bottle and dissolved in DMF (5 mL). HATU (110.2 mg, 0.29 mmol) and DIPEA (0.13 mL) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight, then concentrated under reduced pressure and purified by column chromatography to yield product B9-4 (305.3 mg, 81% yield).

[0461] LC-MS: 1556.7[M+H] +

[0462] Step 4: Synthesis of compound B9-5

[0463] Compound B9-4 (360.0 mg, 0.23 mmol) was added to a 50 mL single-necked vial and dissolved in DCM (10 mL). Diethylamine (0.46 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to obtain the crude product B9-5 (310.4 mg, 100.6% yield).

[0464] LC-MS: 1334.5[M+H] +

[0465] Step 5: Synthesis of Compound B9-6

[0466] Compounds B9-5 (220.0 mg, 0.16 mmol) and B4-1 (53.5 mg, 0.19 mmol) were added to a 50 mL single-necked bottle and dissolved in DMF (5 mL). HATU (72.2 mg, 0.19 mmol) and DIPEA (0.088 mL) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was purified by column chromatography to afford product B9-6 (196.3 mg, 65% yield).

[0467] LC-MS: 1586.7[M+H] +

[0468] Step 6: Synthesis of Compound B9-7

[0469] Compound B9-6 (330.0 mg, 0.21 mmol) was added to a 50 mL single-necked vial and dissolved in DCM (3 mL). TFA (0.6 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to afford product B9-7 (271.9 mg, 88% yield).

[0470] LC-MS: 1486.6[M+H] +

[0471] Step 7: Synthesis of Compound B9

[0472] Compound 1-1 (50.0 mg, 0.056 mmol) and compound B9-7 (251.7 mg, 0.17 mmol) were added to a 25 mL single-necked flask and dissolved in methanol (5 mL). Triethylamine (0.005 mL) was added to the resulting solution. The reaction mixture was stirred at 60°C overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified to obtain compound B9 (11.2 mg, 9.2% yield).

[0473] LC-MS: 1100.2 [M / 2+H] +

[0474] Example B10

[0475]

[0476] Referring to the preparation method of compound B9, compound B10 (9.8 mg, yield: 8.5%) was obtained by purification via liquid preparative chromatography.

[0477] LC-MS: 1026.2[M / 2+H] +

[0478] Example B11

[0479]

[0480] The synthetic route is as follows:

[0481]

[0482] Step 5: Synthesis of Compound B11-2

[0483] Compound B6-3 (300.0 mg, 0.27 mmol) and B11-1 (165.4 mg, 0.33 mmol) were added to a 50 mL single-necked bottle and dissolved in DMF (5 mL). HATU (125.4 mg, 0.33 mmol) and DIPEA (0.15 mL) were added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was purified by column chromatography to afford product B11-2 (307.3 mg, 71% yield).

[0484] LC-MS: 1588.8[M+H] +

[0485] Step 6: Synthesis of Compound B11-3

[0486] Compound B11-2 (220.0 mg, 0.14 mmol) was added to a 50 mL single-necked vial and dissolved in DCM (3 mL). TFA (0.6 mL) was added to the resulting solution. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to afford product B11-3 (183.3 mg, 89% yield).

[0487] LC-MS: 1488.6[M+H] +

[0488] Step 7: Synthesis of Compound B11

[0489] Compound 1-1 (50.0 mg, 0.056 mmol) and compound B11-3 (252.1 mg, 0.17 mmol) were added to a 25 mL single-necked flask and dissolved in methanol (5 mL). Triethylamine (0.005 mL) was added to the resulting solution. The reaction mixture was stirred at 60°C overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified to obtain compound B11 (11.8 mg, 9.5% yield).

[0490] LC-MS: 1101.2 [M / 2+H] +

[0491] Example B12

[0492]

[0493] Referring to the preparation method of compound B11, compound B12 (10.6 mg, yield: 9.1%) was obtained by purification via liquid preparative chromatography.

[0494] LC-MS: 1034.2 [M / 2+H] +

[0495] Example B13

[0496]

[0497] Referring to the preparation method of compound B7, compound B13 (11.3 mg, yield: 8.8%) was obtained by purification via liquid preparative chromatography.

[0498] LC-MS: 1150.8 [M / 2+H] +

[0499] Example B14

[0500]

[0501] Referring to the preparation method of compound B7, compound B14 (10.7 mg, yield: 7.8%) was obtained by purification via liquid preparative chromatography.

[0502] LC-MS: 1217.9 [M / 2+H] +

[0503] Coupling Example:

[0504] Example A1 ADC analysis method

[0505] 1. Determination of DAR value using hydrophobic chromatography HIC-HPLC

[0506] Sample preparation: The sample was diluted to 3.0 mg / mL with mobile phase B, centrifuged at 12000 rpm for 10 min, and the

[0507] The supernatant was used for HPLC analysis;

[0508] Chromatographic conditions:

[0509]

[0510] Gradient elution program:

[0511]

[0512]

[0513] DAR value calculation formula:

[0514] DAR = Σ (weighted peak area) / 100, that is, DAR = (D0 peak area ratio × 0 + D1 peak area ratio × 1 + D2 peak area ratio × 2 + D3 peak area ratio × 3 + D4 peak area ratio × 4 + D5 peak area ratio × 5 + D6 peak area ratio × 6 +

[0515] D7 peak area ratio × 7 + D8 peak area ratio × 8) / 100;

[0516] 2. Determination of ADC purity by size-exclusion chromatography-HPLC: Sample preparation: Sample concentration 1.0-5 mg / mL, filtered through a 0.22 μm filter membrane; Experimental instrument: Agilent 1260 Infinity II Bio-Inert LC System; Chromatographic column: TOSOH, TSKgel G3000SWxL, 5 μm, 7.8 mm × 300 mm; Mobile phase: 0.2 M PB, 5-15% isopropanol, pH 7.0; Flow rate: 0.5-1 mL / min; Detection wavelength: 280 nm & 360 nm; Column temperature: room temperature; Sample load: 30 μg; SEC chromatography elution method: isocratic elution.

[0517] The PB used in this disclosure refers to a sodium phosphate buffer solution composed mainly of sodium dihydrogen phosphate and sodium dihydrogen phosphate. Disodium dihydrogen phosphate and sodium dihydrogen phosphate buffer solutions of different pH values ​​are usually prepared using sodium dihydrogen phosphate and sodium dihydrogen phosphate solutions of the same concentration.

[0518] 3. Residual Small Molecule Determination: Dilute the reference product to 0.03 mg / ml with DMSO. Take 50 μl of each diluted reference product solution and ADC sample, add 4 μl of saturated sodium chloride solution, and then add 146 μl of methanol. Mix thoroughly, centrifuge, and take the supernatant for injection.

[0519] Chromatographic conditions:

[0520]

[0521] Gradient elution program:

[0522]

[0523]

[0524] The content of free small molecules was calculated by the external standard method.

[0525] Example A2 Coupling Method 1

[0526] At 37 degrees Celsius, add 1.0-1.5 equivalents of TCEP reducing agent to a PBS buffer (20 mM, pH 6.5) containing 10 mg / mL trastuzumab. React at 37 degrees Celsius for 1-3 hours, stop the reaction, and lower the reaction temperature to 25 degrees Celsius. Add 10 mM dimethyl sulfoxide solution (10-20 equivalents) of the linker-load synthesized in the embodiment, mix well, and react for 1.5-2.5 hours. After the coupling reaction is complete, use desalting chromatography or ultrafiltration to replace the ADC solution with 20 mM His-HAc + 9% sucrose buffer at pH 5.5, then filter through a 0.22 μm PES filter to produce the ADC stock solution, which is then aliquoted according to experimental requirements and frozen at -20°C or -40°C. The absorbance value is measured at 280 nm using the UV method to calculate the antibody concentration, the DAR value is detected using the HIC method, and the ADC purity is detected by SEC-HPLC.

[0527] Table 3 HER2-targeted randomly coupled ADC quality control data

[0528] ADC Name Target Connector-Payload DAR(HIC) SEC (%) Tmab-B1-1 HER2 B1 2.1 98.4 Tmab-B2-1 HER2 B2 2.3 98.7 Tmab-B3-1 HER2 B3 2.2 98.5 Tmab-B4-1 HER2 B4 2.0 98.3 Tmab-B5-1 HER2 B5 1.9 98.3 Tmab-B6-1 HER2 B6 1.8 98.2 Tmab-B7-1 HER2 B7 2.4 98.0 Tmab-B8-1 HER2 B8 2.6 98.6 Tmab-B9-1 HER2 B9 1.7 98.5 Tmab-B10-1 HER2 B10 1.6 98.3

[0529] Example A3 Coupling Method 2

[0530] At 37 degrees Celsius, add 1.8-2.2 equivalents of TCEP reducing agent to a PBS buffer (20 mM, pH 6.5) containing 10 mg / mL trastuzumab. React at 37 degrees Celsius for 1-3 hours, stop the reaction, and lower the reaction temperature to 25 degrees Celsius. Add 10 mM dimethyl sulfoxide solution (10-20 equivalents) of the linker-load synthesized in the embodiment, mix well, and react for 1.5-2.5 hours. After the coupling reaction is complete, use desalting chromatography or ultrafiltration to replace the ADC solution with 20 mM His-HAc + 9% sucrose buffer at pH 5.5, then filter through a 0.22 μm PES filter to produce the ADC stock solution. Aliquot according to experimental requirements and freeze at -20°C or -40°C. Use UV method to measure the absorbance at 280 nm to calculate the antibody concentration, use HIC method to detect the DAR value, and use SEC-HPLC to detect the ADC purity.

[0531] Table 4 HER2-targeted randomly coupled ADC quality control data

[0532] ADC Name Target Connector-Payload DAR(HIC) SEC (%) Tmab-B1-2 HER2 B1 4.0 98.8 Tmab-B2-2 HER2 B2 4.2 98.5 Tmab-B3-2 HER2 B3 4.1 98.7 Tmab-B4-2 HER2 B4 4.3 98.2 Tmab-B5-2 HER2 B5 3.8 98.0 Tmab-B6-2 HER2 B6 3.9 98.1 Tmab-B7-2 HER2 B7 4.2 98.4 Tmab-B8-2 HER2 B8 4.5 98.5 Tmab-B9-2 HER2 B9 4.3 98.3 Tmab-B10-2 HER2 B10 3.7 98.0

[0533] Example A4 Coupling Method 3

[0534] At 37°C, 20 equivalents of TCEP reducing agent were added to a 10 mg / mL trastuzumab antibody solution (25 mM histidine buffer, pH 6.5). The reaction was allowed to proceed at 37°C for 2 hours, and the reaction was stopped. A 10 mM dimethyl sulfoxide solution (5 equivalents) of the linker-load synthesized in the example was added, mixed, and reacted for 2 hours. After the coupling reaction was completed, the ADC solution was exchanged for 25 mM His-HAc + 9% sucrose buffer at pH 5.5 using desalting chromatography or ultrafiltration, and then filtered through a 0.22 μm PES filter to produce an ADC stock solution. The solution was aliquoted according to experimental requirements and frozen at -20°C or -40°C. The absorbance was measured at 280 nm using the UV method to calculate the antibody concentration, the DAR value was determined using the HIC method, and the ADC purity was determined using SEC-HPLC.

[0535] Table 5 HER2 targeted bridging ADC quality control data

[0536] ADC Name Target Connector-Payload DAR(HIC) SEC (%) Tmab-B11 HER2 B11 3.8 98.9 Tmab-B12 HER2 B12 4.1 98.7 Tmab-B13 HER2 B13 4.0 98.7 Tmab-B14 HER2 B14 4.2 98.2

[0537] Biological evaluation

[0538] The present disclosure is further described and explained below in conjunction with test examples, but these embodiments are not intended to limit the scope of the present disclosure.

[0539] Test Example 1: Inhibitory activity of the disclosed loaded compound on cancer cells

[0540] The purpose of the experiment is to detect the in vitro inhibitory activity of the loaded compound of the present disclosure on T47D (human breast ductal carcinoma cells), KYSE30 (human esophageal squamous cell carcinoma cells) or EBC-1 (human lung squamous cell carcinoma cells).

[0541] Experimental equipment:

[0542] 96-well transparent flat-bottom white plate (Corning, #3610)

[0543] RPMI1640 culture medium (Gibco, #A10491-01)

[0544] MEM medium (Gibco, #11095080)

[0545] Fetal Bovine Serum (Sigma-Aldrich, #F8687-500ML)

[0546] Luminescent Cell Viability Assay (Promega, #G7572 / G7571)

[0547] Experimental methods:

[0548] Human breast cancer cells T47D (Guangzhou Jinio, Catalog No.: JNO-H0372), human esophageal squamous cell carcinoma cells KYSE30 (Nanjing Kebai, Catalog No.: CBP60457), and human lung cancer squamous cell carcinoma cells EBC-1 (Nanjing Kebai, Catalog No.: CBP60091) were washed with PBS and trypsinized with 0.25% Trypsin-EDTA for approximately 3-10 minutes. Digestion was terminated with complete cell culture medium, and the cells were centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded and the cells were resuspended in complete cell culture medium. The cells were counted using a cell counter and adjusted to the desired cell density. 90.0 μL of cell suspension was added to each well (1500 cells / well for KYSE30, 1500 cells / well for T47D and EBC-1), and the cell plates were incubated overnight at 37°C in a 5% CO2 cell culture incubator.

[0549] A DMSO control group and a test article group were set up in the experiment, and the compound eribulin was used as a positive control compound. The cell plate was removed from the incubator to observe the cell attachment status. After the cells attached, 10.00 μL of sample (starting at a final concentration of 10 μM, diluted 5-fold, and 9 concentrations) was added to each well. The plate was gently shaken and placed in the incubator for incubation.

[0550] After 3 days of incubation, 100.0 μL / well CellTiter-Glo TM(Promega, catalog number: G7572 / G7571) working solution, shake on a constant temperature shaker to lyse the cells, and read the plate on a microplate reader after 10 minutes.

[0551] The calculation formula of cell proliferation inhibition rate is: cell proliferation inhibition rate = (1-RLU 供试品孔 / RLU DMSO对照孔 )×100%.

[0552] Data analysis: GraphPad Prism 8.0 software was used to plot the sample concentration log value as the horizontal axis and the inhibition percentage as the vertical axis. Nonlinear regression (curve fit) analysis was performed on the data to obtain the IC of each test sample. 50 Please see Table 6 for the specific results.

[0553] Table 6

[0554]

[0555] The results showed that the loaded compound disclosed herein had a significant inhibitory effect on T47D cells, KYSE30 cells or EBC-1 cells.

[0556] Test Example 2: Pharmacokinetic Evaluation of the Disclosed Loaded Compound in Rats

[0557] Experimental purpose: To evaluate the metabolic kinetics of the compounds of the present disclosure in rats.

[0558] SD rats (Beijing Weitonglihua Laboratory Animal Technology Co., Ltd.) were randomly divided into groups of 4 per group and injected once with the sample (preparation: 4.0% DMSO + 96.0% (10% hydroxypropyl-β-cyclodextrin-normal saline)) at a dose of 1 mpk, diluted according to the dose). Plasma (0.2 mL) was collected before administration and 5 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours after administration. The plasma sample concentration was determined by LC-MS, and the pharmacokinetic parameters were calculated. The results are shown in Table 7.

[0559] Table 7 PK parameters of the disclosed loading compounds in rats

[0560]

[0561] The experimental results show that compared with eribulin, the disclosed loaded compound has a shorter in vivo half-life and a faster in vivo clearance rate in rats.

Claims

1. A compound represented by general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof; in: R 1 and R 2 The atoms it is connected to form Ring A is selected from a 4-membered monocyclic heterocyclyl, a 5- to 10-membered spiro heterocyclyl, and a 5- to 10-membered bridged heterocyclyl; Ring B is selected from a 5- to 7-membered monocyclic heterocyclyl, a 3-membered monocyclic heterocyclyl, and a 5- to 10-membered heteroaryl; or R 1 、R 2 are the same or different and are each independently selected from hydrogen atoms, deuterium atoms, C 1-6 Alkyl, C 1-6 Alkoxy, -C(O)NR n1 R n2 、-C(O)R o1 、-C(O)OR o2 、-S(O) m NR n1 R n2 、-S(O) m R o3 , 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl, and R 1 and R 2 At least one of the following is selected from a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group, and a 5- to 10-membered heteroaryl group; wherein the C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 、-C(O)NR n3 R n4 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl; R 3 Selected from hydrogen atoms, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, -C(O)NR n1 R n2 、-C(O)R o1 、-C(O)OR o2 , 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 、-C(O)NR n3 R n4 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl; Each R 4 are the same or different and are each independently selected from hydrogen atoms, deuterium atoms, C 1-6 Alkyl, -OR o 、-NR n1 R n2 、-C(O)NR n1 R n2 、-C(O)R o1 、-C(O)OR o2 、-S(O) m NR n1 R n2 、-S(O) m R o3 , 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 、-C(O)NR n3 R n4 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl; Each R 5 are the same or different and are each independently selected from deuterium atoms, C 1-6 Alkyl, -OR o 、-NR n1 R n2 、-C(O)NR n1 R n2 、-C(O)R o1 、-S(O) m NR n1 R n2 , 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 、-C(O)NR n3 R n4 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl; R o 、R o1 、R o2 、R o3 、R o4 、R o5 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 , hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl; R n1 、R n2 、R n3 and R n4 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C(O)NR n5 R n6 、-C(O)R o1 、-C(O)OR o2 , 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl group, 3 to 8 membered cycloalkenyl group, 6 to 10 membered aryl group and 5 to 10 membered heteroaryl group; wherein, the C 1-6 Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n7 R n8 、-C(O)NR n7 R n8 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, C 1-6 Alkoxy, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl; or R n1 and R n2 、R n3 and R n4 Together with the nitrogen atoms to which they are attached, they form a 3- to 8-membered heterocyclic group; wherein the 3- to 8-membered heterocyclic group is optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n7 R n8 、-C(O)NR n7 R n8 、-C(O)R o1 、-C(O)OR o2 , hydroxyl, C 1-6 Alkoxy, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl; R n5 、R n6 、R n7 and R n8 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, hydroxy C 1-6 alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl; m is 0, 1, or 2; n is 0, 1, 2, 3 or 4; p is 1, 2, 3 or 4; provided that the compound represented by the general formula (I) is not the following CAS number compounds: 1299493-27-8, 1299470-71-5, 1299470-63-5, 253128-81-3, 253128-80-2, 253128-76-6, 1299493-35-8, 1299493-32-5, 1299493-31-4 and 1299493-30-3.

2. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: Ring A is selected from 4-membered monocyclic heterocyclic groups, 7- to 11-membered spiro heterocyclic groups and 7- to 11-membered bridged heterocyclic groups; preferably, Ring A is selected from 3. The compound according to claim 1 or 2, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: Ring B is selected from 6-membered monocyclic heterocyclic groups; preferably, Ring B is selected from 4. The compound according to any one of claims 1 to 3, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Each R 4 are the same or different and are each independently selected from a hydrogen atom, a hydroxyl group and -CH2OH.

5. The compound according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R 5 for 6. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 At least one of them is selected from a 3- to 8-membered bridged ring group optionally substituted by an amino group; preferably, R 1 and R 2 At least one of which is selected from optionally substituted by amino More preferably, R 1 and R 2 At least one selected from 7. A compound represented by general formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof; in: R 2 and R 3 are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl, deuterated C 1-6 Alkyl, amino substituted C 1-6 Alkyl, halogenated C 1-6 alkyl, The condition is that R 2 A hydrogen atom or C 1-6 When alkyl, R 3 Not hydrogen or C 1-6 Alkyl, and the compound represented by general formula (II) is not the compound with CAS number 2973388-27-9.

8. The compound according to claim 7, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: R 3 Selected from hydrogen atoms, methyl groups, 9. The compound according to claim 7 or 8, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: R 2 Selected from hydrogen atoms, 10. The compound according to any one of claims 1 to 9, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a compound represented by general formula (IA), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; in: Ring C is selected from a 4-membered monocyclic heterocyclyl containing 1 to 3 N atoms, a 5- to 10-membered spiro heterocyclyl, a 5- to 10-membered bridged heterocyclyl, a 5- to 7-membered monocyclic heterocyclyl and a 3-membered monocyclic heterocyclyl; Y is absent or selected from hydrogen atom, hydroxyl group, amino group, -(CH2) r OH, -C(O)(CH2) r OH; t is 0, 1, 2, 3, or 4; r is 0, 1, 2, or 3; Each R 6 are the same or different and are each independently selected from deuterium atoms, C 1-6 Alkyl, -OR o 、-NR n1 R n2 、-C(O)NR n1 R n2 、-C(O)R o1 、-S(O) m NR n1 R n2 , 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n3 R n4 、-C(O)NR n3 R n4 、-C(O)R o4 、-C(O)OR o5 , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from the group consisting of alkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered cycloalkenyl, optionally substituted 6- to 10-membered aryl, and optionally substituted 5- to 10-membered heteroaryl; R o 、R n1 、R n2 、R o1 、R 3 、R n3 、R n4 、R o4 、R o5 , m as described in any one of claims 1 to 9.

11. The compound according to claim 10, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: Ring C is selected from 12. The compound according to claim 10 or 11, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: Y is selected from -C(O)CH2OH.

13. The compound according to any one of claims 1 to 12, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

14. A compound represented by general formula (IB), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: in: Ab represents an antibody or antigen-binding fragment; L represents a linker connecting Ab and the warhead drug molecule P; u is selected from 1-8; P is The compound shown, its stereoisomer or a pharmaceutically acceptable salt thereof; R 1 、R 2 、R 3 As defined in claim 1; or P is The compound shown, its stereoisomer or its pharmaceutically acceptable salt; Ring C, Y, R 6 , tAs defined in claims 10 to 12.

15. The compound according to claim 14, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: Selected from the following compound fragments: Preferably, Selected compound fragments:

16. The compound according to claim 14 or 15, its stereoisomer or pharmaceutically acceptable salt thereof, wherein said L is -L1-L2-L3-L4-, wherein, One end of L1 is connected to the Ab, and one end of L4 is connected to the warhead drug molecule; wherein: L1 is selected from the following groups, and the end of L1 marked with an asterisk * is connected to the Ab: L2 is selected from chemical bonds, The C-terminus of L2 is connected to L3, and the other end is connected to L1; a is the same or different at each occurrence and is independently any integer from 0 to 20; b is the same or different at each occurrence and is independently any integer from 0 to 20; L3 is selected from a polypeptide residue consisting of 2-6 amino acids, and the C-terminus of the polypeptide residue is connected to L4; L4 is selected from a chemical bond, -NH-CH2-, The C-terminus is connected to the warhead drug molecule, and the -NH-terminus is connected to L3.

17. The compound according to any one of claims 14 to 16, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein L2 is selected from a chemical bond, 18. The compound according to any one of claims 14 to 17, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein L3 is selected from GFG, GGFG, GGGFG, GGVA, V-Cit, VA; preferably, L3 is selected from GGFG, VA.

19. The compound according to any one of claims 14 to 18, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein L4 is selected from 20. The compound according to any one of claims 14 to 19, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein L is selected from the following fragments: in, "*" indicates the position where the linker is connected to the warhead drug molecule, and the other end indicates the position where the linker is connected to the Ab.

21. The compound according to any one of claims 14 to 20, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein Selected from the following excerpts:

22. The compound according to any one of claims 1 to 21, its stereoisomer or pharmaceutically acceptable salt thereof, wherein the Ab is selected from anti-Her2 antibody, anti-Trop2 antibody, anti-Claudin18.2 antibody; preferably, the Ab is selected from Trastuzumab, Pertuzumab, Sacituzumab, Zolbetuximab.

23. The compound according to any one of claims 1 to 22, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a compound represented by general formula (IB-1), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: in: Ab, u as defined in claim 14; Ring C, R 6 , Y, t as defined in any one of claims 10 to 12; R 3 As defined in any one of claims 1 to 12.

24. The compound according to any one of claims 14 to 23, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a compound represented by general formula (IB-2), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

25. The compound according to any one of claims 14 to 24, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, which is selected from the following compounds or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof: in, u is 1-8.

26. A compound selected from the group consisting of the following compounds or pharmaceutically acceptable salts or stereoisomers thereof:

27. A pharmaceutical composition comprising a compound according to any one of claims 1 to 26, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

28. Use of the compound according to any one of claims 1 to 26, its stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 27 in the preparation of a medicament for treating and / or preventing cancer.

29. The use according to claim 28, wherein The cancer is selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer, colon cancer, rectal cancer, colorectal cancer, leukemia, bone cancer, skin cancer, thyroid cancer, pancreatic cancer and lymphoma.

Citation Information

Patent Citations

  • Macrocyclic analogs and methods of their use and preparation

    WO1999065894A1